This activity is supported by an unrestricted educational grant from Kala Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Elizabeth Yeu, MD
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease, and Refractive Surgery
Assistant Professor
Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, VA
Stephen Pflugfelder, MD
Professor of Ophthalmology
James and Margaret Elkins Chair
Director, Ocular Surface Center
Baylor College of Medicine
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Elizabeth Yeu, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Advanced Vision Group, Alcon, Allergan, Avellino, Bausch + Lomb, BioTissue, BVI, BlephEx, Bruder, Carl Zeiss Meditec, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Glaukos, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LayerBio, Lensar, Melt, Merck, Mynosys, Novartis, Ocular Science, Ocusoft, Omeros, Oyster Point Pharmaceuticals, Science Based Health, Sight Sciences, Sun Pharmaceutical Industries, Surface, Tarsus, TearLab, Thea, TopCon, and Visus. Research/Grants: Alcon, BioTissue, Johnson & Johnson Vision, Tarsus, TopCon, and TearLab. Stock/Shareholder: Advanced Vision Group, Avellino, BlephEx, CorneaGen, Expert Opinion, LayerBio, Mati, Melt, Modernizing Medicine, Ocular Science, Orasis, Oyster Point Pharmaceuticals, Staar, Tarsus, and Visus.
Stephen Pflugfelder, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Grant/Research Support: Dompe. Consultant: Allergan, Dompe, Kala Pharmaceuticals, Kowa, and Senju.
The Evolve and The Fundingsland staff and planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Kala Pharmaceuticals.
